Kelly Davio

November 06, 2019

France has experimented with financial incentives to reward the prescribing of biosimilars. These incentive structures include shared savings for centers that acquire medicines at lower costs, as well as biosimilar prescribing targets.

November 05, 2019

During the International Society for Pharmacoeconomics and Outcomes Research 2019 meeting being held in Copenhagen, Denmark, 3 teams of researchers presented findings that show that, despite the fact that Europe’s biosimilars market is far more mature than that of the United States, the region still sees setbacks from stakeholder perceptions of biosimilars and from policies that do not adequately incentivize biosimilar use.

November 05, 2019

The FDA has approved Ziextenzo (pegfilgrastim-bmez), Sandoz’s biosimilar pegfilgrastim referencing Neulasta. The biosimilar was approved to decrease the incidence of infection, as manifested by febrile neutropenia, in patients receiving myelosuppressive anticancer treatment. Sandoz plans to launch the product this year.

November 04, 2019

UnitedHealthcare has revised its community and commercial plans’ coverage of erythropoiesis-stimulating agents. Effective January 1, 2020, patients who are receiving the reference epoetin alfa, Epogen or Procrit, will be required to switch to Pfizer’s biosimilar, Retacrit.

November 04, 2019

The International Society for Pharmacoeconomics and Outcomes Research is holding its Europe 2019 meeting this week in Copenhagen, Denmark, and the savings that biosimilars can afford European healthcare systems are a hot topic at this year’s event. Two studies presented on Monday explored how Amgen’s biosimilar bevacizumab (Mvasi) and biosimilar trastuzumab (Kanjinti) could produce significant cost savings for hospitals in the Italian healthcare system.

November 01, 2019

The ONWARD study included patients who initiated therapy with the biosimilar, those who switched from the reference infliximab, or those who switched from a different biologic therapy.

October 31, 2019

This week, during the Academy of Managed Care Pharmacy Nexus 2019 meeting, held in National Harbor, Maryland, healthcare practitioners have gathered to share insights into patient care. Among the groups presenting new findings are 2 research teams that have investigated patterns of use for biosimilar and follow-on products in the United States, and their findings provide insight into how biosimilars are progressing in the US market.

October 31, 2019

With new research presented this month, and with new biosimilars in the pipeline that target inflammatory bowel disease (IBD), October was a notable month for biosimilars in the gastroenterology space.

October 30, 2019

The American Society of Clinical Oncology (ASCO) today released its third annual National Cancer Opinion Survey, results of which highlight the added stress that the financial burden of treatment places on patients with cancer.

October 30, 2019

Biosimilars are beginning to gain momentum, even in the sluggish US market, evidenced by strong US and global sales reported this month by some of the top biosimilar players.